Status:
COMPLETED
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination wit...
Eligibility Criteria
Inclusion
- Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)
- Insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximum 14 days within the last 3 months)
- Treatment with one or two oral anti-diabetic drugs (OADs): metformin, sulfonylurea, other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 month at a stable maximum tolerated dose or at least half maximum allowed dose according to locally approved summary of product characteristics (SPC)
- HbA1c, 7.0 - 11.0 % (both inclusive)
- Body Mass Index (BMI), 25.0 - 37.0 kg/m\^2 (both inclusive)
Exclusion
- Metformin contraindication according to local practice
- Thiazolidinedione (TZD) treatments within the previous three months prior to Visit 1
- Any systemic treatment with products, which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3 months prior to randomisation
- Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial product
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT00614055
Start Date
January 1 2008
End Date
July 1 2008
Last Update
March 20 2017
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Alès, France, 30100
2
Novo Nordisk Investigational Site
Brest, France, 29609
3
Novo Nordisk Investigational Site
La Rochelle, France, 17019
4
Novo Nordisk Investigational Site
Le Creusot, France, 71200